HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Molineux, G. Articles by McNiece, I. Search for Related Content PubMed PubMed Citation Articles by Molineux, G. Articles by McNiece, I.

An Analysis of the Effects of Combined Treatment with rmGM-CSF and PEG-rHuMGDF in Murine Bone Marrow Transplant Recipients

Amgen, Inc., Department of Developmental Hematology, Thousand Oaks, California, USA

Key Words. Megakaryocyte growth and development factor • PEG-rHuMGDF • GM-CSF • Bone marrow transplant

Correspondence: Dr. Graham Molineux, Department of Developmental Hematology, Amgen, Inc., Amgen Center, Mailstop 99-1-A, 1840 Dehavilland Drive, Thousand Oaks, CA 91320, USA.

We have studied the potential of combination growth factor treatment with GM-CSF and megakaryocyte growth and development factor (MGDF) to stimulate hematopoietic recovery in mice following bone marrow transplantation. More rapid recovery of neutrophils occurred in mice treated with recombinant murine (rm)GM-CSF plus pegylated recombinant human (PEG-rHu)MGDF than carrier treated controls, however this recovery was equivalent to the effect of treatment with rmGM-CSF alone. PEG-rHuMGDF stimulated a more rapid recovery of platelets with no effect on neutrophil recovery. At the two tested doses of rmGM-CSF (72 and 200 µg/kg/day) the platelet recovery was inferior to that in carrier treated mice. Also, the addition of rmGM-CSF to PEG-rHuMGDF had a dose-related negative impact on platelet recovery compared to PEG-rHuMGDF alone.

These data suggest that the use of combination therapy in some clinical indications may lead to unexpected results. Furthermore, careful dosage studies may be necessary to identify the full potential of combined growth factors to obtain additive or synergistic effects on multilineage hematopoietic reconstitution in vivo.

This article has been cited by other articles:

				C. N. Coleman Linking Radiation Oncology and Imaging through Molecular Biology (or Now That Therapy and Diagnosis Have Separated, It's Time to Get Together Again!) Radiology, July 1, 2003; 228(1): 29 - 35. [Abstract] [Full Text] [PDF]

				A. M. Farese, T. J. MacVittie, L. Roskos, and R. B. Stead Hematopoietic Recovery Following Autologous Bone Marrow Transplantation in a Nonhuman Primate: Effect of Variation in Treatment Schedule with PEG-rHuMGDF Stem Cells, January 1, 2003; 21(1): 79 - 89. [Abstract] [Full Text] [PDF]

				D. J. Kuter and C. G. Begley Recombinant human thrombopoietin: basic biology and evaluation of clinical studies Blood, November 15, 2002; 100(10): 3457 - 3469. [Abstract] [Full Text] [PDF]

				R. Abraham and R. L. Basser Megakaryocyte Growth and Development Factor: A Review of Early Clinical Studies Oncologist, October 1, 1997; 2(5): 311 - 318. [Abstract] [Full Text] [PDF]